
Sanofi SA (NASDAQ:SNY) on Wednesday released topline data from a phase 2 study evaluating the efficacy and safety of AlphaMedix (212Pb-DOTAMTATE).
The patients had unresectable or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs), positive somatostatin analog imaging, and at least one site of measurable disease.